Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infliximab as disease-modifying therapy.

Geert R D'Haens1

  • 1Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium. geert.dhaens@uz.kuleuven.ac.be

European Journal of Gastroenterology & Hepatology
|March 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impaired keratinization activity in perianal Crohn's fistulas is associated with poor prognosis.

Journal of Crohn's & colitis·2026
Same author

Upfront medical or surgical treatment in Crohn's disease - Authors' reply.

The lancet. Gastroenterology & hepatology·2026
Same author

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.

Inflammatory bowel diseases·2026
Same author

In Memoriam: Brian G. Feagan, MD, FRCPC (1954-2025).

Gastroenterology·2026
Same author

Colonic biopsy-associated microbial signatures are predictive of response to anti-TNFα biological therapy in Crohn's disease.

Frontiers in cellular and infection microbiology·2026
Same author

Etrasimod Treatment Modulates Circulating and Lymph Node-Derived Lymphocytes in Crohn's Disease.

International journal of molecular sciences·2026

Tumour necrosis factor (TNF) drives Crohn's disease inflammation. Infliximab, an anti-TNF antibody, effectively treats active and fistulating Crohn's disease by inducing inflammatory cell apoptosis.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Crohn's disease pathophysiology involves significant mucosal inflammation.
  • Tumour necrosis factor (TNF) is a key mediator in this inflammatory process.

Purpose of the Study:

  • To review the role of infliximab in managing Crohn's disease.
  • To highlight its efficacy and safety based on clinical trial data.

Main Methods:

  • Review of controlled clinical trials on infliximab in Crohn's disease.
  • Analysis of data regarding efficacy in active and fistulating disease.
  • Assessment of safety aspects and appropriate indications.

Main Results:

  • Infliximab demonstrates potent anti-inflammatory effects, likely via apoptosis of inflammatory cells.

Related Experiment Videos

  • Controlled trials confirm its efficacy in both active and fistulating Crohn's disease.

    • Conclusions:

    • Infliximab is a valuable therapeutic tool for Crohn's disease management.
    • Established indications and safety data support its use in clinical practice.